Quadrant Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Quadrant Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-29,568	Closed	-$1.53M	–	64
2016 Q1	$1.53M	Buy	29,568 +4,372	+17%	+$227K	1.3%	40
2015 Q4	$1.77M	Buy	25,196 +600	+2%	+$40.9K	1.43%	34
2015 Q3	$1.53M	Buy	24,596 +1,070	+5%	+$84.3K	1.3%	37
2015 Q2	$1.98M	Sell	23,526 -1,080	-4%	-$84K	1.69%	30
2015 Q1	$1.85M	Sell	24,606 -489	-2%	-$34.2K	1.59%	33
2014 Q4	$1.56M	Buy	25,095 +45	+0.2%	+$2.56K	1.34%	38
2014 Q3	$1.3M	Buy	25,050 +300	+1%	+$15.3K	1.24%	42
2014 Q2	$1.27M	Buy	+24,750	New	+$1.12M	1.22%	43

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Quadrant Capital Management's XBI Position: Q2 2016 in Review

Quadrant Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2016, closing a stake of 29,568 shares — an estimated $1.53M sold.

Quadrant Capital Management first reported a position in XBI in Q2 2014 and held it in 8 quarters. The position peaked at $1.98M in Q2 2015. 201 funds tracked by Wall St. Rank hold XBI as of Q2 2016.

Quadrant Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2016 after selling out during the quarter.
Quadrant Capital Management sold 29,568 State Street SPDR S&P Biotech ETF shares in Q2 2016, an estimated $1.53M.
Quadrant Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2014 and held it in 8 quarters.
Quadrant Capital Management's State Street SPDR S&P Biotech ETF position peaked at $1.98M in Q2 2015.
201 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2016.

Based on Quadrant Capital Management's 13F filing for Q2 2016, filed 21 Jul 2016.